Organogenesis (NASDAQ:ORGO) Stock Falls 3.6% – What’s Next?

Organogenesis (NASDAQ:ORGO)’s share price fell 3.6% on Friday. The stock traded as low as $0.9330 and last traded at $0.9932. Approximately 1,338,803 shares were traded during trading, an increase of 64% from the average daily volume of 815,558 shares. The stock had previously closed at $1.03.

Wall Street Analysts Forecast Growth

ORGO has been the subject of a number of analyst reports. Wall Street Zen upgraded Organogenesis from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Weiss Ratings downgraded Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Finally, Truist Financial reduced their price objective on Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $4.33.

Organogenesis Price Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.00. The stock’s fifty day moving average is $1.45 and its 200-day moving average is $2.07. The stock has a market cap of $127.80 million, a PE ratio of -1.15 and a beta of 1.27.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%. The firm had revenue of $43.76 million for the quarter, compared to analyst estimates of $54.27 million.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Organogenesis in the second quarter valued at approximately $17,616,000. Dimensional Fund Advisors LP increased its stake in Organogenesis by 5.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock worth $6,851,000 after acquiring an additional 160,026 shares during the last quarter. Deutsche Bank AG acquired a new stake in Organogenesis during the second quarter worth $4,146,000. Renaissance Technologies LLC increased its stake in Organogenesis by 30.5% during the first quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company’s stock worth $2,532,000 after acquiring an additional 249,838 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Organogenesis by 39.8% in the first quarter. SG Americas Securities LLC now owns 790,766 shares of the company’s stock valued at $1,874,000 after purchasing an additional 225,265 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.